Idenix Pharmaceuticals Inc (NASDAQ:IDIX) develops new drugs

Boston, MA 04/05/2013 (wallstreetpr) – Idenix Pharmaceuticals Inc(NASDAQ:IDIX) on May 30, 2002 is a bio-pharmaceutical company, chiefly engaged in the discovery and development of drugs for the treatment of human viral diseases. At present the Company’s primary research and development is focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. Of late the FDA granted Fast Track designation for IDX719. On January 25, 2013, the Company has entered into a non-exclusive collaboration agreement with other pharmaceutical firms for the clinical evaluation of all oral DAA HCV combination therapies.

Idenix Pharmaceuticals Inc (NASDAQ:IDIX) is currently trading at $3.51, down by 4.36% With a total trading volume of around $491M, the shares of the company are regularly traded on the NASDAQ.  A study of the last year’s quoted stocks reveals that the price ranged between $ 3.21 to as high as $ 11.30, with an average daily trading of  1.77 million shares.

Despite the presence of several pharmaceutical giants on NASDAQ, the prospect of Idenix Pharmaceuticals is bright. Of late, trading analysis reports clearly indicate that investors have shown a great dependence on the company, despite the gross negative trend in the money market in the holistic view of the present macro economic situation. This has obviously been due to the aggressive expansion strategy of the Idenix Pharmaceuticals in recent times. Its latest research in the field of treatment of highly incurable diseases like HIV, Hepatitis B, and related viral diseases has tremendous marketing potential.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Donna Fago

I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at recently due to my passion for the markets.